| Dr Ruben Oreste Flores Sanchez, DC | |
|
Calle 24 Aa3 Flamboyan Gardens, Bayamon, Pr, PR 00959 | |
| (787) 395-7555 | |
| (787) 395-7556 |
| Full Name | Dr Ruben Oreste Flores Sanchez |
|---|---|
| Gender | Male |
| Speciality | Chiropractor |
| Location | Calle 24 Aa3 Flamboyan Gardens, Bayamon, Pr, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124790076 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 800 (Puerto Rico) | Primary |
| Provider Name | Live Movement Chiropractic & Wellness Clinic Psc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1184147639 PECOS PAC ID: 3375876600 Enrollment ID: O20190531000681 |
News Archive
CML is a blood cancer that can be controlled by continuously taking an expensive type of medicine called a tyrosine kinase inhibitor (TKI). In almost all patients, stopping TKI treatment results in recurrence of CML.
Boston Scientific Corporation today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples for diagnosing and staging malignancies in organs adjacent to the gastrointestinal tract. The Expect Needle received FDA clearance and CE Mark approval earlier this year and is being marketed in the U.S., Europe and other international markets.
The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.
The fight against HIV and tuberculosis (TB) in Eastern Europe and Central Asia is being threatened by cuts in global health funding, according to "a report [.pdf] by leading European non-governmental health organizations," Reuters reports.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ruben Oreste Flores Sanchez, DC Calle 24 Aa3 Flamboyan Gardens, Bayamon, Pr, PR 00959 Ph: (787) 395-7555 | Dr Ruben Oreste Flores Sanchez, DC Calle 24 Aa3 Flamboyan Gardens, Bayamon, Pr, PR 00959 Ph: (787) 395-7555 |
News Archive
CML is a blood cancer that can be controlled by continuously taking an expensive type of medicine called a tyrosine kinase inhibitor (TKI). In almost all patients, stopping TKI treatment results in recurrence of CML.
Boston Scientific Corporation today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples for diagnosing and staging malignancies in organs adjacent to the gastrointestinal tract. The Expect Needle received FDA clearance and CE Mark approval earlier this year and is being marketed in the U.S., Europe and other international markets.
The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.
The fight against HIV and tuberculosis (TB) in Eastern Europe and Central Asia is being threatened by cuts in global health funding, according to "a report [.pdf] by leading European non-governmental health organizations," Reuters reports.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.
› Verified 2 days ago